Please select the eligibility criteria that correspond to the clinical trial below.
Title: Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector
Brief Summary: The main side-effect of Implanon is the changes induces in bleeding patterns including amenorrhea, infrequent to irregular bleeding and frequent and prolonged bleeding; without any previous symptom and it was characterized as "breakthrough bleeding" (BTB). BTB is the main causes of early discontinuations. Unfortunately, there is no indication to predict prior to insertion what sort of bleeding pattern any individual woman may have after insertion and the proposed treatments were disappointed. Nevertheless, previous studies with other progestin-only contraceptives (including Implanon) provide evidence that the provision of adequate and intensive counseling to potential users and new acceptors about bleeding changes can help to improve method continuation.

The availability of Implanon in the public sector could help in the development of strategies to introduce the method in the public sector network and the training of medical residents.


Options:
A: Inclusion Criteria:

* Age 18-35
* BMI \> 30kg/m2
* Proof of a normal breast and pelvic exam within last 9 months
* Self reported normal menstrual periods (24-35 days)
* Good general health
* In the investigator's opinion, are subject's veins suitable the repeat blood draws dictated by study protocol
* Single progesterone level during screening visit ≥ 3ng/mL
* Hematocrit ≥ 36%

Exclusion Criteria:

* Contradictions to COCs (history of deep vein thrombosis,myocardial infection, uncontrolled hypertension, pulmonary embolus, diabetes with vascular changes, stroke, migraines with neurologic changes, breast cancer, impaired liver function, uncontrolled thyroid disease, hypersensitivity or allergy to birth control)
* Smoker (must smoke 0 cigarettes)
* Actively seeking/involved in a weight loss program
* Currently pregnant/seeking pregnancy in the next 6 months
* Currently breast-feeding
* Past or current diagnosis of polycystic ovarian disease
* Recent use of birth control (Depot medroxyprogesterone: 6 months, Progestin implants: 6 months, Oral contraceptives, patch or ring: 2 months, Hormone impregnated IUD: 6 months)
* Currently taking medication that interferes with COC's (Rifampin, Carbamazepine, St. John's Wort)
B: Inclusion Criteria:

* Women 18 to 40 years
* New users of Implanon, IUDs and the LNG-IUS TCu380A

Exclusion Criteria:

* Contraindications to contraceptive methods
C: Inclusion Criteria:

* 18-40 years
* new users of DMPA
* BMI\<30kg/m²

Exclusion Criteria:

* diabetes mellitus and 2 present or fasting glucose\> 100mg/dl and / or blood glucose\> 140mg/dl after ingestion of 75mg of oral glucose
* first-degree relatives with diabetes mellitus
* period of lactation
* hypertension, with or without treatment
* hyper and hypothyroidism
* chronic renal failure
* transplant of any organ
* women using drugs that may be related to weight gain and / or development of insulin resistance and chronic use of corticosteroids, antipsychotics, statins, and thiazide,
* hirsutism and/or hyperandrogenism
* polycystic Ovary Syndrome (PCOS)
* women with acanthosis nigricans
* women who have used depoprovera at some point in their reproductive lives,
* women who have performed bariatric surgery
D: Inclusion Criteria:

* Be willing to be randomized to receive the implant at the enrollment visit or in three months;
* Be 18-44 years of age;
* Not known to be HIV-positive;
* Have a negative pregnancy test at baseline;
* Not currently using an intrauterine device or system, a contraceptive implant, or injectable contraception;
* Not planning to start use an intrauterine contraceptive device or system or injectable contraception in the next three months;
* Not have had surgical sterilization or plan to have it in the next three months;
* Not have medical contraindication to implant use, including lactation within first 6 weeks postpartum, acute deep venous thrombosis or pulmonary embolism, lupus, migraine with aura, unexplained vaginal bleeding, current or history of breast cancer,severe cirrhosis, liver tumors, history of stroke, and current or history of ischaemic heart disease;
* Be willing to return to the clinic for two follow-up visits over the next three months; and
* Be otherwise a good candidate for study participation based on investigator assessment

Answer: B